|
Arecor Therapeutics PLC on Monday said it has entered into a formulation development collaboration with California-based, clinical-stage biotechnology firm, Skye Bioscience Inc, as the pair seek to address the unmet needs in metabolic disease. The Cambridgeshire, England-based biopharmaceutical company said the partnership aims to develop a novel, higher-concentration formula of Skye’s CB1 inhibitor, nimacimab, through using Arecor’s proprietary formulation technology platform, Arestat. Shares in Arecor Therapeutics rose 18% to 48.49 pence on Monday afternoon in London. Skye is currently evaluating nimacimab in its phase 2a CBeyond clinical trial for treatment of obesity, with initial data expected later this year. Under the collaboration, Skye will fund Arecor’s development activities with an option to licence rights to the new formulation and associated intellectual property to advance developments and commercialisation. Arecor Chief Executive Sarah Howell said: ‘We are pleased to partner with Skye Bioscience to support the development of a novel, enhanced formulation of nimacimab, a promising first-in-class candidate with the potential to address significant unmet needs in metabolic disease. ‘We have entered 2025 with significant momentum and this marks the third formulation development collaboration to be established by Arecor with partner companies so far this year. Together these have a total pre-license deal value in excess of £1 million, and provide Arecor with significant upside potential from future licensing opportunities.’ Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
